Archive
2021
- Klinische Fase 1a studie met onze lead compound INT-1B3
- Vacancy for a highly motivated PhD student to join the RnD Research team with a keen interest on “ The endo-lysosomal processes in metabolic disease development and therapeutic efficacy”
2020
- InteRNA steunt de campagne Innovaties in Oncologie van @Mediaplanet. Leer meer over verschillende innovaties in oncologie zoals immuuntherapieën van thought leaders, zoals Ton Schumacher online of in de New Scientist (24 maart 2020)
- InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
- Recently a short movie about InteRNA and it’s lead compound for the treatment of cancer was broadcasted in the RTL4/RTLZ program “Zo kan het ook”. Watch the video with the latest news here
- CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
2019
- InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
- InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
- InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting
- InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting
2018
- New Journal of Neuroscience paper shows that our functional screening platform for miRNA drug candidates works also nicely outside Oncology
- InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting
- InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
- InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting
2017
2016
2015
2014
2013
- InteRNA's R&D collaboration partner UMC St. Radboud receives grant from Stichting voor de Technische Wetenschappen
- SomantiX B.V. and InteRNA Technologies B.V. obtain a MIT R&D collaboration grant
- InteRNA Technologies also receives notice of allowance for its melanoma lead compound miRNA-3157 in Australia
- InteRNA Technologies partner in €11.5 Million EU Framework Program 7
- MiRacle Consortium led by InteRNA Technologies and VU University Medical Center
2012
- InteRNA Technologies B.V. announces full consolidation of its subsidiary InteRNA Genomics B.V. as of July 1, 2012
- InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product
2011
- InteRNA Technologies Strengthens its R&D Team Nijmegen/Utrecht (the Netherlands)
- Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
- InteRNA Technologies announces establishment of Supervisory Board
2010
- InteRNA Technologies announces establishment of Scientific Advisory Board Utrecht (the Netherlands)
- InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands)
2009
- InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
- New small and medium enterprises join TIPharma by signing two new projects
- InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways